Despite years of fully suppressive antiretroviral therapy (ART), HIV persists in its hosts and is never eradicated. One major barrier to eradication is that the virus infects multiple cell types that may individually contribute to HIV persistence. Tissue macrophages are critical contributors to HIV pathogenesis1, 2, 3; however, their specific role in HIV persistence during long-term suppressive ART has not been established4, 5, 6. Using humanized myeloid-only mice (MoM), we demonstrate that HIV infection of tissue macrophages is rapidly suppressed by ART, as reflected by a rapid drop in plasma viral load and a dramatic decrease in the levels of cell-associated viral RNA and DNA. No viral rebound was observed in the plasma of 67% of the ART-treated animals at 7 weeks after ART interruption, and no replication-competent virus was rescued from the tissue macrophages obtained from these animals. In contrast, in a subset of animals (~33%), a delayed viral rebound was observed that is consistent with the establishment of persistent infection in tissue macrophages. These observations represent the first direct evidence, to our knowledge, of HIV persistence in tissue macrophages in vivo.
At a glance
- The macrophage: a therapeutic target in HIV-1 infection. Mol. Cell. Ther. 2, 10 (2014). &
- Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology 9, 82 (2012). , &
- The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 28, 2175–2187 (2014). , , , &
- Macrophages and HIV-1: an unhealthy constellation. Cell Host Microbe 19, 304–310 (2016). &
- HIV and cells of macrophage/dendritic lineage and other non–T cell reservoirs: new answers yield new questions. J. Leukoc. Biol. 74, 631–634 (2003). , , , &
- Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir. Chem. Chemother. 20, 63–78 (2009). &
- Macrophages sustain HIV replication in vivo independently of T cells. J. Clin. Invest. 126, 1353–1366 (2016). et al.
- Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 5, e8829 (2010). et al.
- Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog. 8, e1002732 (2012). et al.
- Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J. Reprod. Immunol. 88, 195–203 (2011). , , &
- Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12, 1316–1322 (2006). et al.
- Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2012). et al.
- Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10, e1003872 (2014). et al.
- Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel. J. Am. Med. Assoc. 308, 387–402 (2012). et al.
- HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582–1586 (1996). , , , &
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995). et al.
- Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995). et al.
- Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS 30, 761–769 (2016). et al.
- Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118–130 (2007). , &
- Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 98, 658–663 (2001). et al.
- CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. PLoS Pathog. 10, e1004467 (2014). et al.
- Quantitation of productively infected monocytes and macrophages of simian immunodeficiency virus–infected macaques. J. Virol. 90, 5643–5656 (2016). et al.
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011). et al.
- Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013). et al.
- Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J. Infect. Dis. 212, 258–263 (2015). et al.
- Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22, 1131–1135 (2008). et al.
- An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834 (2013). et al.
- The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc. Natl. Acad. Sci. USA 89, 3290–3294 (1992). , , &
- Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV. PLoS Pathog. 12, e1005535 (2016). et al.
- HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22, 1583–1588 (2008). et al.
- Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828–1835 (2013). et al.
- Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 207, 1694–1702 (2013). et al.
- Eradication of HIV from the brain: reasons for pause. AIDS 25, 577–580 (2011). &
- HIV-1 target cells in the CNS. J. Neurovirol. 21, 276–289 (2015). , , &
- Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 8, e55943 (2013). et al.
- HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell–only mouse (TOM) model. Retrovirology 10, 121 (2013). et al.
- Nonparametric methods for measurements below detection limit. Stat. Med. 28, 700–715 (2009). , , &
- Statistical methods for assays with limits of detection: serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. J. Carcinog. 10, 12 (2011). et al.
- Estimating population distributions when some data are below a limit of detection by using a reverse Kaplan–Meier estimator. Epidemiology 21 (Suppl. 4), S64–S70 (2010). et al.
- Supplementary Figures and Tables (1,930 KB)
Supplementary Figures 1–5 & Supplementary Tables 1,2.